Clinical Trials Logo

Clinical Trial Summary

Men with Idiopathic Hypogonadotropic Hypogonadism (IHH) lack a hormone called gonadotropin releasing hormone (GnRH). This hormone is important for starting puberty, maintaining testosterone levels, and fertility. The purpose of this study is to research the effects of treating IHH men with GnRH for 7 days.


Clinical Trial Description

Despite variability in the triggers, timing, and pace of sexual maturity between species, all species utilize the final pathway of hypothalamic secretion of gonadotropin releasing hormone (GnRH) to initiate and maintain the reproductive axis. Thus, GnRH is required for reproductive competence in the human. The classic studies from the 1970s clearly demonstrate that pulsatile release of GnRH from the hypothalamus is a prerequisite for physiologic gonadotrope function. Absence, decreased frequency or decreased amplitude of pulsatile GnRH release results in the clinical syndrome of hypogonadotropic hypogonadism (HH). The phenotypic expression of GnRH deficiency in the human demonstrates considerable heterogeneity. Defining the physiology of GnRH is critical to understanding the clinical heterogeneity of isolated GnRH deficiency and its comparison to other conditions resulting in hypogonadotropic hypogonadism (HH). The overall goal of this protocol is to investigate the neuroendocrine control of reproduction and specifically the physiology and pathophysiology of GnRH secretion and action in the human male. Subjects will be selected from a group of adult men (18-65 years)based on the demonstration of a low testosterone level (<100 ng/dL) in association with low or inappropriately normal gonadotropin levels. All patients will undergo an initial assessment that includes an overnight 12-hour frequent blood sampling study to determine their degree of endogenous GnRH secretion. Following the overnight evaluation, subjects will have daily outpatient visits for 7 consecutive days when they will receive a GnRH bolus followed by 2hrs of blood sampling. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00493961
Study type Interventional
Source Massachusetts General Hospital
Contact
Status Completed
Phase Phase 1
Start date January 1999
Completion date November 17, 2009

See also
  Status Clinical Trial Phase
Completed NCT01403532 - Sequential Therapy for Hypogonadotropic Hypogonadism Phase 4
Recruiting NCT03687606 - Efficacy and Safety of Long Term Use of hCG or hCG Plus hMG in Males With Isolated Hypogonadotropic Hypogonadism (IHH) Phase 4
Recruiting NCT04463316 - GROWing Up With Rare GENEtic Syndromes
Terminated NCT03118479 - Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism (IHH) Phase 1
Active, not recruiting NCT04733274 - Patient and Healthcare Professional Views on Genetic/Genomic Information and Testing
Recruiting NCT01601171 - Genetics of Reproductive Disorders (Including Kallmann Syndrome) and Cleft Lip and/or Palate
Completed NCT01438034 - Kisspeptin in the Evaluation of Delayed Puberty Phase 1
Recruiting NCT00914823 - Kisspeptin Administration in the Adult Phase 1
Completed NCT01914172 - Health Needs of Patients With Kallmann Syndrome N/A
Completed NCT00392457 - Investigating the Regulation of Reproductive Hormones in Adult Men N/A
Recruiting NCT05971836 - The Molecular Basis of Inherited Reproductive Disorders
Completed NCT00494169 - Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders
Enrolling by invitation NCT00623116 - A Study to Characterize Epidemiology, Clinical and Genetic Features of Kallmann Syndrome in Finland N/A
Recruiting NCT02880280 - Human Menopausal Gonadotropin Combining With Human Chorionic Gonadotropin Treat Congenital Hypogonadotropic Hypogonadism Phase 4
Terminated NCT00064987 - Follicle Stimulating Hormone (FSH) to Improve Testicular Development in Men With Hypogonadism Phase 2
Completed NCT00392756 - Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS) Phase 1